Additive Obinutuzumab in Rituximab-Refractory Membranous Nephropathy: Caution in Effect Attribution
American Journal of Nephrology · 08.10.2026
DOI: 10.1159/ajn/ablag009 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Nephrology, online erschienen am 08.10.2026. Verfasst von Emre Cankaya und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Ankara Bilkent City Hospital, Ankara, Turkey. Die Arbeit nennt 1 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Ankara Bilkent City Hospital, Ankara, Turkey.
Zitieren
APA
Cankaya, E., Aslum, B., & Yenigun, E. C. (2026). Additive Obinutuzumab in Rituximab-Refractory Membranous Nephropathy: Caution in Effect Attribution. American Journal of Nephrology. https://doi.org/10.1159/ajn/ablag009
Vancouver
Cankaya E, Aslum B, Yenigun EC. Additive Obinutuzumab in Rituximab-Refractory Membranous Nephropathy: Caution in Effect Attribution. American Journal of Nephrology. 2026. doi:10.1159/ajn/ablag009
BibTeX
@article{Cankaya2026,
author = {Cankaya, Emre and Aslum, Burak and Yenigun, Ezgi Coskun},
title = {Additive Obinutuzumab in Rituximab-Refractory Membranous Nephropathy: Caution in Effect Attribution},
journal = {American Journal of Nephrology},
year = {2026},
doi = {10.1159/ajn/ablag009}
}
EUVIMED